At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 281 enrolled
Drug / intervention
Ranibizumab 0.5 mg +1 moredrug
Likely dose
Ranibizumab 0.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Development of New Geographic Atrophy in Patients With Neovascular (Wet) Age-related Macular Degeneration: a Comparison of Ranibizumab and Aflibercept
In Brief
A Phase 4 clinical trial evaluating Ranibizumab 0.5 mg and Aflibercept 2.0 mg for Age-Related Macular Degeneration. Completed, enrolled 281 participants across 22 sites.
Detailed Summary
The purpose of this study was to compare the development of new geographic atrophy in patients with wet Age-related Macular Degeneration (AMD) when treated with either ranibizumab or aflibercept over 24 months. Geographic atrophy is an advanced form of AMD that can result in the progressive and irreversible loss of visual function over time.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAge-Related Macular Degeneration
CountriesAustralia
Collaborators--
Timeline
Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartApr 2014
First PostedMay 2014
Primary CompletionNov 2017
TodayJul 2026
First PostedMay 2, 2014
Enrollment StartApr 11, 2014
Primary CompletionNov 15, 2017
TodayJul 2, 2026
Enrollment to primary: 3.6 yearsPosted 12.2 years ago
Interventions
Ranibizumab 0.5 mgdrug
Administered as an intravitreal injection
Aflibercept 2.0 mgdrug
Administered as an intravitreal injection